HOTBIO - A Holistic Approach to Training a new Generation of Scientists in Marine Biodiscovery

HOTBIO联盟将培训新一代早期科学家，将海洋微生物天然产品从海床带到床边。他们将参与管道的每一个阶段，从微生物分离到化合物纯化和鉴定，再到制造具有理想药物性质的类似物。他们将在获取和利益分享、知识产权和创业方面获得相关技能。从HOTBIO毕业的学生将处于一个独特的地位，可以进入一个充满挑战的劳动力市场，因为他们将在学术界和行业合作伙伴中接受世界领先的研究小组的多学科培训。导师将由工业科学家和最近从MSCA ITN Marpiet毕业的学生提供。HOTBIO财团由来自7个欧洲国家的8名受益者组成，其中包括2名来自非学术部门的成员，该财团将接待10名博士生。另外三名博士生将由瑞士国家教育、研究和创新秘书处提供资金，由两个瑞士合作伙伴接待。除了在欧洲的合作伙伴借调外，学生还将有机会在非洲和亚洲的中低收入国家(LMIC)进行借调，以更深入地了解如何在资源有限的情况下进行现代研究。HOTBIO通过包括计算机辅助药物设计(CADD)、优化化合物的化学合成(即药物化学)、目标去卷积和广泛的ADMET剖析，扩展了传统的海洋生物发现管道。这将把生物活性微生物次级代谢物推进到临床前开发的后期阶段，并将为药物发现过程的初始阶段应针对哪种化合物的决定和优先事项提供信息。下游开发将包括早期项目中的热门化合物。

The HOTBIO consortium will train a new generation of early-stage scientists to take marine microbial natural products from the seabed to the bedside. They will be involved in every stage of the pipeline from microbial isolation through compound purification and identification to making analogues with desirable drug-like properties. They will gain associated skills in access and benefit sharing, intellectual property and entrepreneurship. Students graduating from HOTBIO will be in a unique position to enter a challenging labour market as they will have received multidisciplinary training at world leading research groups in academia as well as at industry partners. Mentorship will be provided by industrial scientists and recent graduates from the MSCA ITN MarPipe. The HOTBIO consortium consists of eight beneficiaries from seven European countries, including two members from non-academic sectors, that will host ten PhD students. Three more PhD students hosted by two Swiss associated partners will be funded by the Swiss State Secretariat for Education, Research and Innovation. In addition to secondments at the partners in Europe, students will also get the opportunity to do secondments in low-to-middle income countries (LMICs) in Africa and Asia to get a deeper understanding of how modern research can be done in resource-limited setting. HOTBIO expands a conventional marine biodiscovery pipeline by including computer aided drug design (CADD), chemical synthesis of optimized compounds (i.e. medicinal chemistry), target deconvolution and extensive ADMET profiling. This will advance the bioactive microbial secondary metabolites to the later stages of preclinical development, and it will also inform the decisions and priorities of what kind of compounds that should be targeted in the initial phase of the drug discovery process. The downstream development will include hit compounds from earlier projects.